Orphandrug — Trading Ideas on TradingView

MBRX Annamycin Fast Track and Orphan Drug Designation from FDA Moleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases. the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. This should be an interesting year for MBRX, which is at all time low now. 52 Week Range 1.64 - 8.78 My price target is $3.8

ORPH Might shoot to the moon This is an interesting stock and I think this will go up quickly strictly due to supply and demand

VRTX Beginning!Fundamental & Chart Not for investment advice, personal notes only Chart: identified key area of support, concerning current H&S pattern, potential downside to next support indicate 17% drop. CMF shows weakness, spending a lot of times in the negatives. So far trend line remains intact, neckline of H&S shows no particular bearish inclination Fundamentals: Core product in strong growth, In January 26, 2021, VRTX announced that it received FDA approval for the use of Trikafta with children ages 6-11 with CF and certain mutations. In January 28, 2021, VRTX announced that it received FDA clearance for its type-1 diabetes investigational medicine and will enter the phase ½ clinical trial. Powerful toppling and bottom line growth, Net income has grown 229% from 2019 to September 2020. Currently seeking acquisition opportunities Let's wait and see

Newest Alert is $CBIO $CBIO Recent Highlights and Upcoming Milestones Recent Highlights: Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis of $0.2 million. Cash, cash equivalents and short-term investments as of March 31, 2017 were $14.5 million The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months. Raised $20.7 million through an underwritten public equity offering that included the full exercise of the underwriters’ over-allotment option to purchase additional shares and warrants on April 12, 2017 Achieved key milestones with CB 2679d/ISU304, the Company’s next-generation coagulation Factor IX, as follows: Investigational New Drug (IND) application approved by the Korean Ministry of Food and Drug Safety (MFDS) Completion of IND-enabling toxicology studies triggered a milestone payment from Catalyst’s collaboration partner, ISU Abxis Advanced the development of marzeptacog alfa (activated), the Company’s next-generation Factor VIIa, including the following accomplishments: Received notice from the European Patent Office that the opposition period, for a patent granted to Catalyst, has expired and no opposition has been filed Selected a global contract research organization, INC Research, to conduct the Phase 2/3 efficacy clinical trial of marzeptacog alfa (activated) in individuals with hemophilia A or B with an inhibitor Anticipated Milestones CB 2679d/ISU304: Initiate a Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B in the second quarter of 2017; the trial will be conducted by Catalyst’s collaborator, ISU Abxis (KOSDAQ: 086890) in South Korea Marzeptacog alfa (activated): Initiate the Phase 2 part of a Phase 2/3 efficacy clinical trial in individuals with hemophilia A or B with an inhibitor in the fourth quarter of 2017